Danaher (NYSE:DHR) Downgraded to Hold at StockNews.com

StockNews.com lowered shares of Danaher (NYSE:DHRFree Report) from a buy rating to a hold rating in a research note published on Tuesday morning.

A number of other brokerages have also recently weighed in on DHR. Barclays raised their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an equal weight rating in a report on Wednesday, April 24th. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a neutral rating in a report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a hold rating to a buy rating and raised their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Citigroup raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a buy rating in a report on Wednesday, April 24th. Finally, TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a buy rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $269.29.

View Our Latest Research Report on Danaher

Danaher Price Performance

NYSE DHR opened at $251.80 on Tuesday. Danaher has a 12 month low of $182.09 and a 12 month high of $269.11. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm has a market capitalization of $186.51 billion, a PE ratio of 42.61, a P/E/G ratio of 3.89 and a beta of 0.85. The company’s 50 day simple moving average is $255.36 and its 200 day simple moving average is $246.19.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the business earned $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Danaher will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s payout ratio is 18.31%.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock worth $37,536,717 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DHR. Cape Investment Advisory Inc. bought a new position in shares of Danaher during the 4th quarter valued at $25,000. Tsfg LLC raised its holdings in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. bought a new position in shares of Danaher during the 4th quarter valued at $29,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the 1st quarter valued at $30,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.